Stock comparison
Generate Biomedicines
Hamilton Lane
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GENB
Generate Biomedicines
Market cap
$1.86B
Sector
Financials
HLNE
Hamilton Lane
Market cap
$5.04B
Sector
Financials
Overall winner
Hamilton Lane HLNE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GENB | HLNE | Winner |
|---|---|---|---|
| Warren Buffett | 52D | 76C | HLNE |
| Benjamin Graham | 44D | 65B | HLNE |
| Philip Fisher | 78B | 77C | GENB |
| Peter Lynch | 100A | 53C | GENB |
| Joel Greenblatt | 4F | 43D | HLNE |
| Charlie Munger | 77D | 73B | GENB |
| Terry Smith | 79B | 76B | GENB |
Side-by-side metrics
| Metric | GENB | HLNE |
|---|---|---|
| Market cap | $1.86B | $5.04B |
| P/E (TTM) | - | 14.1x |
| EV/EBIT | - | 15.7x |
| ROIC (TTM) | -89.38% | 14.52% |
| Gross margin | 100.0% | 69.23% |
| Net margin | -6.37% | 30.59% |
| Revenue CAGR 5y | 55.89% | 20.19% |
| EPS CAGR 5y | - | 17.91% |
| Debt / Equity | - | 0.4x |
| Dividend yield | 0.0% | 2.44% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GENB leads on
- EV/EBIT-vs 15.7x+154%
- P/E (TTM)-vs 14.1x+128%
- Debt / Equity-vs 0.4x+127%
- Revenue CAGR 5y55.89%vs 20.19%+64%
HLNE leads on
- ROIC (TTM)14.52%vs -89.38%+116%
- Net margin30.59%vs -6.37%+105%
- Dividend yield2.44%vs 0.0%+100%
- Market cap$5.04Bvs $1.86B+63%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.